Latest hit for Irish stock exchange as pharma services firm Hvivo to delist from Euronext 

Clinical trials group joins running list of companies to delist from Irish stock exchange as it moves to 'consolidate trading' to its primary London listing

The pharma firm was once among the best performers on the Irish stock exchange as it tapped millions of euro in contracts from the British government and other institutions to advise on human clinical trials used in testing covid-19 vaccines

Irish-listed clinical trials group Hvivo has announced it will remove its shares from the Irish stock market later this year.

The company, previously named Open Orphan, said it would cancel its admission to trading on Euronext Growth from September 2nd, joining the running list of companies to exit the struggling Dublin stock market.